Mammary Cell News Volume 13.40 | Oct 28 2021

    By
    Justin.choi
    -
    0
    111







    2021-10-28 | MCN 13.40


    Mammary Cell News by STEMCELL Technologies
    Vol. 13.40 – 28 October, 2021
    TOP STORY

    An EMT–Primary Cilium–GLIS2 Signaling Axis Regulates Mammogenesis and Claudin-Low Breast Tumorigenesis

    Researchers showed that GLIS family zinc finger 2 (GLIS2) inactivation promoted mammary stem cell stemness, and that GLIS2 was required for normal mammary gland development, while GLIS2 inactivation induced the proliferative and tumorigenic capacities of the mammary tumor–initiating cells of claudin-low breast cancers.
    [Science Advances]

    Full Article
    Explore scientific events this November with the Science Events Calendar.
    PUBLICATIONSRanked by the impact factor of the journal

    Regulatory T Cells Promote Cancer Immune-Escape through Integrin αvβ8-Mediated TGF-β Activation

    The authors showed that in mouse melanoma and breast cancer models, regulatory T cells expressing the β8 chain of αvβ8 integrin were the main cell type in the tumors that activated TGFβ, produced by the cancer cells and stored in the tumor micro-environment.
    [Nature Communications]

    Full Article

    Clonal Populations of a Human TNBC Model Display Significant Functional Heterogeneity and Divergent Growth Dynamics in Distinct Contexts

    Scientists analyzed clonal dynamics in subclonal population mixtures and used DNA barcode technology that revealed selection for distinct clonal populations in different in vitro and in vivo environmental contexts.
    [Oncogene]

    Abstract

    Triple-Negative Breast Cancer Cells Rely on Kinase-Independent Functions of CDK8 to Evade NK-Cell-Mediated Tumor Surveillance

    Investigators used a murine model of orthotopic breast cancer to study the tumor-intrinsic role of cyclin-dependent kinase 8 (CDK8) in TNBC and linked CDK8 to programmed death-ligand 1 expression.
    [Cell Death & Disease]

    Full Article

    Immune and Nonimmune Mechanisms Mediate the Mental Stress-Induced Tumor Growth in a Xenograft Model of Breast Cancer

    Researchers applied unpredictable stress stimuli to breast tumor-bearing mice and established a xenograft model of breast cancer that suffered mental stress, followed by behavioral tests, tumor growth tracking, immune analysis, miRNA screening, and tumor cell proliferation analysis.
    [Cell Death & Disease]

    Full Article

    Breast Cancer Dormancy Is Associated with a 4NG1 State and Not Senescence

    The authors thoroughly characterized the dormant D2.OR and ZR-75-1, and proliferative D2A1 breast cancer cell line models in vivo and in vitro, and assessed if there was overlap between a dormant and a senescent phenotype.
    [npj Breast Cancer]

    Full Article

    Oncogene-Mediated Metabolic Gene Signature Predicts Breast Cancer Outcome

    Scientists demonstrated that Trop2 was overexpressed in TNBC, and that Trop2 was downregulated and delayed TNBC cell and tumor growth which supported the oncogenic role of Trop2 in breast cancer.
    [npj Breast Cancer]

    Full Article

    NRIP1 Is Activated by C-JUN/C-FOS and Activates the Expression of PGR, ESR1 and CCND1 in Luminal a Breast Cancer

    Investigators identified differentially expressed genes via a comparison between luminal A breast cancer subtypes and normal mammary ductal cells from healthy donors.
    [Scientific Reports]

    Full Article

    The Regulatory Effect of Hyaluronan on Human Mesenchymal Stem Cells’ Fate Modulates Their Interaction with Cancer Cells In Vitro

    Researchers explored breast cancer and glioblastoma multiforme cell lines MDA-MB-321 and U87-MG, and evaluated the impact of hyaluronan on tumor promoting features of bone marrow-derived mesenchymal stem cells, and their interaction with tumor cells.
    [Scientific Reports]

    Full Article
    Connect with us via LiveChat to ask your scientific support questions
    REVIEWS

    Mammographic Density, Endocrine Therapy and Breast Cancer Risk: A Prognostic and Predictive Biomarker Review

    Investigators assess the evidence that a reduction in mammographic density following endocrine therapy for breast cancer prevention in women without previous breast cancer, or for treatment in women with early‐stage hormone receptor‐positive breast cancer, is a prognostic or predictive biomarker.
    [Cochrane Database of Systematic Reviews]

    Abstract

    The Current Status of Risk-Stratified Breast Screening

    The authors summarize the established and emerging evidence regarding several critical dependencies for successful risk-stratified breast screening: risk prediction model performance, epidemiological studies, qualitative research on feasibility, and acceptability.
    [British Journal of Cancer]

    Full Article

    The Classification of Neuroendocrine Neoplasms of the Breast and Its Clinical Relevance

    Scientists critically revise the current classification of neuroendocrine neoplasms of the breast, underlining its lights and shadows and focusing on the identification of diagnostic histopathological criteria.
    [Virchows Archiv]

    Abstract
    INDUSTRY AND POLICY NEWS

    Context Therapeutics® and Wisconsin Oncology Network Announce First Patient Dosed in Phase II Trial of ONA-XR in Metastatic Breast Cancer

    Context Therapeutics, Inc. and Wisconsin Oncology Network, announced the first patient has been dosed in the Phase II trial of onapristone in combination with fulvestrant for patients with ER-positive, and HER2-negative metastatic breast cancer after progression on endocrine therapy and CDK 4/6 Inhibitors.
    [Context Therapeutics, Inc.]

    Press Release

    European Commission Approves Merck’s KEYTRUDA® Plus Chemotherapy as Treatment for Certain Patients with Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer

    Merck, Inc. announced that the European Commission has approved KEYTRUDA® , in combination with chemotherapy for the first-line treatment of locally recurrent unresectable or metastatic TNBC in adults whose tumors express PD-L1, and who have not received prior chemotherapy.
    [Merck, Inc.]

    Press Release
    FEATURED EVENT

    2nd AACR-KCA Conference on Precision Medicine in Solid Tumors

    November 10 – 11, 2021
    Seoul, Korea & Online

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Fellow – Cancer Biology

    Georgetown University School of Medicine – Washington, District of Columbia, United States

    Postdoctoral Training Fellow – Target Validation and DNA Damage

    Institute of Cancer Research – London, United Kingdom

    Postdoctoral Position – Translational Oncology

    Medical University of Vienna – Vienna, Austria

    Postdoctoral Fellow – Tumor Heterogeneity and Development of Resistant Cancer

    City of Hope – Los Angeles, California, United States

    Postdoctoral Fellow – Molecular and Cellular Oncology

    The University of Texas MD Anderson Cancer Center – Houston, Texas, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Mammary Cell News Twitter